Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanomix Corp NNMX

Healthcare Medical Devices
Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient... see more

Recent & Breaking News (OTCPK:NNMX)

Boston Therapeutics Announces New COO, Loraine V. Upham

GlobeNewswire February 20, 2018

Boston Therapeutics, Inc. Introductory Social Media Launch (www.bostonti.com)

GlobeNewswire January 16, 2018

Boston Therapeutics, Inc. Expands Partnership with APC to Distribute in Korea

GlobeNewswire December 14, 2017

Boston Therapeutics, Inc. Announces New Dosing Regimen for BTI320

GlobeNewswire December 6, 2017

Boston Therapeutics Shareholder Update

GlobeNewswire November 17, 2017

BOSTON THERAPEUTICS Reports Data from the POC Asia Trial at the American Diabetes Association’s 77th Scientific Sessions

GlobeNewswire June 19, 2017

Boston Therapeutics secures $1 Million financing for the first phase Multi-Centre International Ph II-III Trial

Marketwired April 26, 2017

Boston Therapeutics Business Update

Marketwired February 7, 2017

Boston Therapeutics Announces Innovation Grant

Marketwired October 13, 2016

Boston Therapeutics Reports Positive Topline Data From Proof of Concept Asia Trial

Marketwired October 6, 2016

Boston Therapeutics Completes Private Offering, Appoints New CEO

Marketwired October 3, 2016

Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin

Marketwired December 29, 2015

Boston Therapeutics, Inc. Reports Third Quarter Results and Provides Corporate Update

Marketwired November 20, 2015

Boston Therapeutics Completes Enrollment for BTI-320 Clinical Trial

Marketwired October 6, 2015

Boston Therapeutics Pays Off Convertible Promissory Notes

Marketwired September 29, 2015

Boston Therapeutics' BTI-320 in Clinical Trial Significantly Reduces Both Glucose and Fructose Levels in Blood

Marketwired September 15, 2015

Boston Therapeutics, Inc. Reports Second Quarter Results and Provides Corporate Update

Marketwired August 13, 2015

Boston Therapeutics Nominates Philip Getter to Board of Directors

Marketwired August 6, 2015

Presentation Schedule Now Available for RedChip's July 22-23 Global Online CEO Conference

GlobeNewswire July 15, 2015

Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong

Marketwired July 8, 2015